(13) reported that among patients with synchronous BM, those with EGFR mutation were more likely to have a larger number of metastatic sites compared to those without EGFR mutations, whereas there was no difference in the size of the largest brain tumors regardless of the EGFR mutation status. This evidence concerns the gene EGFR and brain neoplasm.